Breaking news on cholesterol
Data From Mipomersen Phase 3 Trial In heFH Patients Presented At ESC published
Wed, 01 Sep 2010 06:00:00 PDT
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden...
Netherlands Study Shows Need For Dose Management Care When Switching To Generic Statins published
Wed, 01 Sep 2010 00:00:00 PDT
Research conducted in the Netherlands has highlighted the need for care when switching patients under treatment for high cholesterol from branded to generic drug families. The study shows that much of the switching can result in patients inadvertently receiving non-equivalent doses, potentially leading to an increased risk of downstream heart disease and stroke...
Grapefruit's Bitter Taste Holds A Sweet Promise For Diabetes Therapy published
Fri, 27 Aug 2010 01:00:00 PDT
Naringenin, an antioxidant derived from the bitter flavor of grapefruits and other citrus fruits, may cause the liver to break down fat while increasing insulin sensitivity, a process that naturally occurs during long periods of fasting...
Expanded Lipoprotein Testing, VAP® Cholesterol Test Discussed At National Lipid Association Summer Clinical Lipid Update published
Thu, 26 Aug 2010 03:00:00 PDT
Atherotech Diagnostics Lab will exhibit its VAP® Cholesterol Test in booth 105 at the National Lipid Association (NLA) Summer 2010 Clinical Lipid Update. The meeting takes place August 27-29 at the Mayflower Hotel in Washington, D.C...
Impax Laboratories Confirms Patent Challenge Relating To VYTORIN(R), 10 Mg/80 Mg published
Mon, 23 Aug 2010 03:00:00 PDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN® (ezetimibe/simvastatin), 10 mg/80 mg. Impax filed its Abbreviated New Drug Application ("ANDA") containing a paragraph IV certification for a generic version of VYTORIN® with the U.S. Food & Drug Administration ("FDA")...
Outlets Should Offer Free Statins With Junk Food Say UK Researchers published
Fri, 13 Aug 2010 02:00:00 PDT
Imagine this: order a cheeseburger and fries, and pick up a free cholesterol-busting statin tablet along with the other free condiments, that's what a group of UK researchers suggests you should be able to do at fast food outlets as a way to offset the increase in heart attack risk from eating junk food...
Amarin's AMR101 Pivotal Phase 3 MARINE Clinical Trial Completes Patient Enrollment And Randomization published
Wed, 11 Aug 2010 02:00:00 PDT
Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial...
Abbott's SIMCOR® (Niacin Extended-Release / Simvastatin) Receives FDA Approval For New Dosage Strengths published
Fri, 06 Aug 2010 03:00:00 PDT
Abbott has received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin - the most commonly prescribed dose of simvastatin - with either 500 mg or 1,000 mg of niacin extended-release...
Disrupting Body Clock Could Keep Triglycerides High, Raising Risk Of Heart Disease published
Thu, 05 Aug 2010 08:00:00 PDT
From studies on mice, researchers in the US have discovered that disrupting the body clock or circadian rhythm could interfere with a normal 24 hour cycle of high and low triglycerides in a way that leaves them at a high level all the time, potentially raising the risk of atherosclerosis and heart disease. You can read how Dr M...
95 Genetic Variants Associated With Cholesterol, Triglycerides, Identified By Scientists published
Thu, 05 Aug 2010 04:00:00 PDT
A global team of researchers co-led by the University of Michigan School of Public Health has discovered or confirmed 95 regions of the human genome where genetic variants are associated with blood cholesterol and triglyceride levels, which are major indicators of heart disease risk...
Genome Scanning Finds Genes For Cholesterol And Heart Disease That Could Be Important Targets For Treatment published
Thu, 05 Aug 2010 02:00:00 PDT
Two international studies published in a leading journal this week have pinpointed genes for cholesterol and heart disease that could be important targets for treatment, and demonstrate the potential clinical value of "genome scanning" or GWAS, genome wide association studies, in developing new diagnostic tests and therapies for diseases with genetic risks...
Low Carb Diet Better For Cardiovascular Health Than Low Fat Diet published
Tue, 03 Aug 2010 10:00:00 PDT
Researchers from of the Center for Obesity Research and Education at Temple University, Philadelphia have revealed that after a two-year comparison, a low-carb diet fares about as well as a low-fat diet with regards to weight loss, but low-carb improves cardiovascular risk factors more...
Modestly High Cholesterol Levels In Young People Can Cause Heart Disease Signs By Age 45 published
Tue, 03 Aug 2010 09:00:00 PDT
Relatively young individuals with slightly abnormal cholesterol levels have a real risk of developing signs of heart disease by the time they are 45 years old, according to a new study published in the peer-reviewed medical journal Annals of Internal Medicine. In a 20-year study, researchers gathered data on 3,258 males and females between the ages of 18 and 30 years...
Cholesterol Levels In Young Adults Predict Risk Of Future Heart Disease published
Tue, 03 Aug 2010 03:00:00 PDT
Young people with even modestly elevated cholesterol levels are more likely to develop coronary artery calcium and atherosclerosis later in life, according to a 20-year study released on August 2 by UCSF researchers...
News From Annals Of Internal Medicine: August 3, 2010 published
Tue, 03 Aug 2010 03:00:00 PDT
At Two Years, Low-carb Diet Beats Low-Fat for HDL-Cholesterol Levels Previous studies comparing low-carbohydrate and low-fat diets have not included comprehensive behavioral treatment. Researchers sought to evaluate the long-term effects of a low-carbohydrate versus a low-fat diet when combined with a comprehensive lifestyle modification program...
Disparities In Cardiovascular Risk Based More On Socioeconomic Status Than Race, Ethnicity published
Tue, 03 Aug 2010 02:00:00 PDT
A new UCLA study suggests that disparities in cardiovascular disease risk in the United States are due less to race or ethnicity than to socioeconomic status...
Abbott's SIMCOR(R) (Niacin Extended-Release / Simvastatin) Receives FDA Approval For New Dosage Strengths published
Thu, 29 Jul 2010 04:00:00 PDT
Abbott received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin - the most commonly prescribed dose of simvastatin - with either 500 mg or 1,000 mg of niacin extended-release...
Abbott's SIMCOR ® ( Niacin Extended-release / Simvastatin ) Receives FDA Approval For New Dosage Strengths published
Thu, 29 Jul 2010 02:00:00 PDT
Abbott (NYSE: ABT) received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin the most commonly prescribed dose of simvastatin with either 500 mg or 1,000 mg of niacin extended-release...
Preventing Heart Problems While Keeping A Cool Head published
Tue, 27 Jul 2010 01:00:00 PDT
Max Planck researchers explain the cause of the flushing effect arising from cholesterol treatment with nicotinic acid. Cholesterol influences the health of our hearts and blood vessels. Conventional treatment attempts to reduce the level of "bad" cholesterol, LDL cholesterol, in the blood plasma...
No Firm Conclusions About HDL Cholesterol Can Be Drawn From JUPITER Sub-analysis published
Sun, 25 Jul 2010 01:00:00 PDT
No firm conclusions about HDL cholesterol can be drawn from JUPITER sub-analysis Sophia Antipolis, 23 July 2010: The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet (1), could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol...
Good Cholesterol Seems Less Important Once Statins Have Lowered Bad Cholesterol published
Fri, 23 Jul 2010 02:00:00 PDT
Results of an international trial suggest that once statins have lowered LDL or "bad" cholesterol, the level of HDL or "good" cholesterol is less important in terms of predicting cardiovascular risk than it is during pre-treatment assessment...
New Links Between Cholesterol And Depression In The Elderly published
Thu, 22 Jul 2010 02:00:00 PDT
Most people know that high cholesterol levels place them at increased risk for heart disease and stroke. Prior research has shown that particular types of strokes contribute to one's risk for depression, and that abnormal blood lipid levels can increase the risk of depression in the elderly...
News From The American Academy Of Family Physicians, July/August 2010 published
Tue, 20 Jul 2010 02:00:00 PDT
American Academy of Family Physicians - Coca-Cola Alliance, Conflict of Interest or Ethical Relationship? In an essay addressing the recent controversy over the American Academy of Family Physicians accepting a large corporate donation from The Coca-Cola Company to fund patient education materials on obesity prevention, family physician and AAFP member Howard Brody, M.D., Ph.D...
Recordati : Positive Conclusion To The Decentralized Procedure For The Approval In Europe Of Pitavastatin (Livazo®) published
Thu, 15 Jul 2010 04:00:00 PDT
Recordati announces the positive outcome of the Decentralized Procedure for the approval of pitavastatin (Livazo®, Alipza® and other brands) in Europe following the communication from the Reference Member State (MHRA, Medicines and Healthcare products Regulatory Agency, UK) and the agreement of all the Concerned Member States which was received by Kowa...
Pfizer Announces European Union Approval Of A New Form Of Lipitor (atorvastatin) For Use In Children published
Wed, 14 Jul 2010 02:00:00 PDT
Pfizer Inc...
)
|
|
